LADX — LadRx Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Cytrx granted type b pre-nda meeting with U.S. FDA for registration pathway with aldoxorubicin
Brief: Cytrx Corp says files for mixed shelf offering of up to $200 mln- SEC filing
Brief: Cytrx Corporation announces $8.1 mln registered direct offering of common stock
Brief: Cytrx reports statistically significant updated results from pivotal phase 3 trial of aldoxorubicin in patients with second-line soft tissue sarcomas
Brief: Cytrx presents positive interim results from on-going clinical trial
Brief: Cytrx Q3 loss $0.13/shr
Brief: Cytrx completes enrollment in lung cancer mid-stage study
Brief: Cytrx reports loss per share of $0.27 for Q2 2016
Brief: CVI Investments reports 7.5 pct passive stake in Cytrx as of July 15
Brief: Cytrx Corp announces pricing of $20 mln public offering
Brief: CytRx reports initial results of aldoxorubicin late-stage trial in soft tissue sarcoma patients
Brief: CytRx presents updated Aldoxorubicin trial results
Brief: Cytrx Corp issued 1.6 mln shares for benefit of claimants of IN RE Cytrx securities litigation
Brief: CytRx reports Q1 loss per share $0.19
Brief: Cytrx to present new clinical data on its cancer drug
Brief: Cytrx presents aldoxorubicin phase 3 clinical trial data
Brief: CytRx secures $40 million long-term loan facility
Brief: CYTRX files for shelf of up to $100 mln
Brief: CytRx Corp Says Aldoxorubicin continues to demonstrate positive clinical activity in phase 2 Glioblastoma trial